Association of Reproductive Health Professionals
Post on 25-Feb-2016
42 Views
Preview:
DESCRIPTION
Transcript
Association of Reproductive Health Professionalswww.arhp.org
Options for Therapeutic Abortion: Manual Vacuum Aspiration and Medication Management
Expert Medical Advisory Committee• Herbert P. Brown, MD• Michelle Forcier, MD, MPH• Emily Godfrey, MD, MPH• Marji Gold, MD • Jini Tanenhaus, PA, MA
Learning Objectives• List four clinical indications for manual vacuum
aspiration (MVA)• List four factors to consider when counseling
women about MVA versus medical management of early pregnancy loss
more…
Learning Objectives (continued)
• List three conditions in a patient that should cause a provider to use caution before providing MVA or medical management of early pregnancy loss
• List at least one medication regimen used for early medication abortion
Module 1:MVA Overview
Unintended Pregnancy in the United States (2001)
Finer LB, Henshaw SK. Perspect Sex Reprod Health. 2006.
Intended
6.3 million pregnancies
Birth
Abortion
Fetal Loss
Unintended
Outcomes of Unintended PregnanciesApproximately 3 million annually in the United States
Finer LB, Henshaw SK. Perspect Sex Reprod Health. 2006.
44% BirthAbortion 42%
Miscarriage/Fetal Demise
14%
Abortions by Length of Pregnancy
Strauss LT, et al. MMWR. 2006
≤89 to 1011 to 1213 to 1516 to 20≥21
Weeks Gestation
61%18%
10%
6%
1%
4%
What Is a Manual Vacuum Aspirator?
Creinin MD, et al. Obstet Gynecol Surv. 2001.; Goldberg AB, et al. Obstet Gynecol. 2004.’ Hemlin J, et al. Acta Obstet Gynecol Scand. 2001.
Manual vacuum aspirator• Has locking valve• Is portable and reusable• Vacuum is equivalent to
electric pump• Efficacy is same as electric
vacuum (98%–99%)• Has semi-flexible plastic cannula
What Is an Electric Vacuum Aspirator?
Creinin MD, et al. Obstet Gynecol Surv. 2001.; Goldberg AB, et al. Obstet Gynecol. 2004.; Hemlin J, et al. Acta Obstet Gynecol Scand. 2001.
Electric vacuum aspirator• Uses an electric pump or
suction machine connected via flexible tubing
• Has a plastic or metal cannula
• Typically used in centralized settings with high caseloads
History of MVA
Bird ST, et al. Contraception. 2003.; Edwards J, et al. Curr Probl Obstet Gynecol Fertil. 1997.; Karman H, et al. Lancet. 1972.
1973: Helms Amendment enacted
1973: USAID sponsors Ipas
1980s: MVA marketed worldwide
1990s: MVA used in >100 countries
Comparison of EVA to MVA
Dean G, et al. Contraception. 2003.
EVA MVAVacuum Electric pump Manual aspiratorNoise Variable Quiet
Portable Not easily YesCannula 4–16 mm 4–12 mmCapacity 350–1,200 cc 60 cc
Suction Constant Decreases to 80% (50 mL) as aspirator fills
Products of Conception (POC)
Edwards J, et al. Am J Obstet Gynecol. 1997.MacIsaac L, et al. Am J Obstet Gynecol. 2000.
Procedure is complete when POC are identified
Electric Suction Machine
MVA Aspirator
Clinical Indications for MVA • Uterine evacuation in the first trimester:
▪ Induced abortion▪ Spontaneous abortion
• Incomplete medication abortion• Uterine sampling• Post-abortal hematometra
Creinin MD, et al. Obstet Gynecol Surv. 2001.; Edwards J, Creinin MD. Curr Probl Obstet Gynecol Fertil.1997.; Castleman LD et al. Contraception. 2006; MVA Label. Ipas. 2007.
Complications with MVA• Very rare • Same as EVA• May include:
▪ Incomplete evacuation▪ Uterine or cervical injury▪ Infection▪ Hemorrhage▪ Vagal reaction
MVA Label. Ipas. 2004.
Putting Abortion into Perspective…
Gold RB, Richards C. Issues Sci Technol. 1990.; Hatcher RA. Contracept Technol Update. 1998.; Mokdad AH, et al. MMWR Recomm Rep. 2003.
Incident Chance of death
Terminating pregnancy < 9 weeks 1 in 500,000
Terminating pregnancy > 20 weeks 1 in 8,000
Giving birth 1 in 7,600
Driving an automobile 1 in 5,900
Using a tampon 1 in 350,000
Post-Abortion Care
Creinin MD, et al. Obstet Gynecol Surv. 2001.; Goldberg AB, et al. Obstet Gynecol. 2004.; Hemlin J, Moller B. Acta Obstet Gynecol Scand. 2001.
• Women desiring pregnancy▪ Vitamin and diet recommendations▪ Toxic-exposure avoidance guidelines
• Women avoiding pregnancy▪ Contraceptive counseling▪ Contraception initiated on day of MVA
MVA vs. EVA Complication RatesMethods• Vacuum aspiration for abortion up to 10 wks LMP• Retrospective cohort analysis• Choice of method (MVA vs. EVA) up to physician• n = 1,002 for MVA; n = 724 for EVA • Charts reviewed for complications
Goldberg AB, et al. Obstet Gynecol. 2004.
more…
MVA vs. EVA Complication Rates (continued)
Goldberg AB, et al. Obstet Gynecol. 2004.
Complications
• 2.5% for MVA• 2.1% for EVA (p = 0.56)• No significant difference
more…*Elective not spontaneous studies
MVA vs. EVA Complication Rates (continued)
Goldberg AB, et al. Obstet Gynecol. 2004.
Choice of MVA vs EVA in procedures
• Attendings: 52% MVA
• Gyn residents: 59% MVA
• Other residents: 76% MVA (p<0.001)
*Elective not spontaneous studies
Conventional Wisdom and Abortion Care
Depineres T, Stewart F. NAF. 2002. ; Castadot RG. Fertil Steril. 1986.Edwards J, Creinin MD. Curr Probl Obstet Gynecol Fertil. 1997.
1970s
•Wait 7+ weeks for lowest risk of complications
Today
• Ultra-sensitive pregnancy tests
• POC inspection• Ultrasound• Medication abortion• MVA• No reason to wait
What Services Do You Provide?
Use index cards provided to answer the following. Do not write your name.• Does your facility currently provide vacuum
aspiration abortions before 6 weeks? ▪ Yes/No
• Are there clinical or program-related barriers to providing early abortion with vacuum aspiration? ▪ Yes/No (If yes, list the most significant barriers.)
Earlier Procedures Are Safer
Bartlet L, et al. Obstet Gynecol. 2004.
Gestational Age
Strongest risk factor for abortion-related
mortality
Abortions at <8 weeks = lowest risk of death
“…Because access to abortions even one week earlier reduces the risk of death…increased access to early abortion services may increase the proportion of abortions performed at the lower-risk, early gestational ages and help reduce maternal deaths.”
Offering Services as Early as Possible
Bartlet L, et al. Obstet Gynecol. 2004.
Early Abortion with Vacuum Aspiration
Author Date N Gestational Age Efficacy
Paul et al. 2002 1,132 (MVA+EVA) <6 98%
Edwards & Carson 1997 1,530 MVA <6 99%
Edwards & Creinin 1997 2,399 MVA <6 99%
Hemlin & Moller 2001 91 MVA <8 98%
Laufe 1977 12,888 “About 6” 98%
Baird TL, Flinn SK. 2001.; Edwards J, Carson SA. Am J Obstet Gynecol. 1997.Edwards J, Creinin MD. Curr Probl Obstet Gynecol Fertil. 1997. Hemlin J, Moller B. Acta Obstet Gynecol Scand. 2001.; Paul ME, et al. Am J Obstet Gynecol. 2002.
Early Abortion with MVA: Study • Methods
▪ 2,399 MVA procedures, < 6 weeks LMP▪ Meticulous inspection of POC immediately after
MVA• Results
▪ 99.2% effective in terminating pregnancy▪ 6 repeat aspirations (0.25%)▪ 14 ectopic pregnancies (0.6%) diagnosed and
treated
Edwards J, Creinin MD. Curr Probl OIbstet Gynecol Fertil. 1997.
Early Abortion with MVA or EVA: Study
Methods• 1,132 women, ≤ 6 weeks LMP• Of 1,093 procedures:
▪ 52% MVA▪ 40% EVA▪ 8% both
• Examination of POC immediately after procedure
Paul ME, et al. Am J Obstet Gynecol. 2002.
more…
Early Abortion with MVA or EVA: Study (continued)
Paul ME, et al. Am J Obstet Gynecol. 2002.
more…
17 of 1,132Required re-aspiration
Results
2.3% of study population
Early Abortion with MVA or EVA: Study (continued)
Paul ME, et al. Am J Obstet Gynecol. 2002.
more…
Failure rates by technique among women with follow-up (95% CI):
1.1% 2.9% 7.5%(0.4%-3.0%) (1.4%-5.7%) (2.1%-18.2%)
MVA EVA Both used
Early Abortion with MVA or EVA: Study (continued)
Of the 750 women with follow-up, 13 experienced other complications:• 4 incomplete abortions• 2 unrecognized ectopic pregnancies • 1 hematometra• 4 pelvic infections• 3 re-aspirations for pain and bleeding despite
negative pathology
Paul ME, et al. Am J Obstet Gynecol. 2002.
MVA and POC: Study
• In group overall ▪ n = 1,726, up to 10 weeks LMP
• Complication rates between MVA and EVA▪ 37 patients at < 6 weeks’ gestation▪ In 35 of 37, provider chose MVA ▪ No re-aspirations needed in patients < 6 weeks
Goldberg AB, et al. Obstet Gynecol. 2004.
more…
MVA and POC: Study (continued)
“…Significantly more re-aspirations for inability to accurately identify the pregnancy occurred in electric group.”
Goldberg AB et al. Obstet Gynecol, 2004
Goldberg AB, et al. Obstet Gynecol. 2004.
Safety and Efficacy: Family Practice Office
Methods• Abortion using MVA, <12 weeks LMP• Retrospective chart review, N = 1,677 • 60% performed by residents under supervision• 40% performed by attendings
Westfall JM, et al. Arch Fam Med. 1998.
more…
Safety and Efficacy: Family Practice Office (continued)
Results• 99.5% effective• 1.3% minor complications• No hospitalizations
Westfall JM, et al. Arch Fam Med. 1998.
Patient Satisfaction
• Both EVA and MVA groups were highly satisfied
• No differences in:▪ Pain▪ Anxiety▪ Bleeding▪ Acceptability ▪ Satisfaction
• More EVA patients were bothered by noiseBird ST, et al. Contraception. 2003.; Dean G, et al. Contraception. 2003.; Edelman A, et al. Am J Obstet Gynecol. 2001.
MVA Safety and Efficacy: Summary
• MVA is simple▪ Easily incorporated into office setting
• Training/Practice Issues▪ Expanding pain management options▪ Ultrasound as needed▪ No sharp curettage▪ Patient-provider interaction▪ Identifying products of conception▪ Instrument processing for multiple use
MVA in Office Settings• Safety and efficacy equivalent to EVA• Portable• Simple• Low cost• Small and quiet
Goldberg AB, et al. Obstet Gynecol. 2004.
Beneficial to incorporate MVA servicesinto the office setting.
Module 2:MVA Procedure
MVA Steps
Gather required supplies
Charge aspirator
Stabilize and anesthetize cervix
Insert cannula
Empty uterus
After counseling and support …
MVA Instruments
Steps for Performing MVA
A step-by-step, one- page poster is
available from the manufacturer to guide clinicians
through the procedure
MVA and Pain
Pain is made worse by:• Fearfulness• Anxiety• Depression
Belanger E, et al. Pain. 1989.; Smith GM, et al. Am J Obstet Gynecol. 1979.Hansen GR, Streltzer J. Emerg Med Clin N Am. 2005.
Effective Pain Management• Respectful, informed, and supportive staff• Warm, friendly environment• Gentle operative technique• Women’s involvement• Effective pain medications
Pain Management Philosophies • Minimize risk/maximize benefit• Take away all pain/all feeling• Get through it
Pain Management Techniques
Lichtengerg ES, et al. Contraception. 2001.Good M, et al. Pain Manag Nurs. 2002.
Local
General or nitrous
Local + IV
10%
32% 58%
With addition of:• Focused breathing: 76%• Visualization: 31%• Localized massage: 14%
Paracervical Block
Regular InjectionDeep Injection
Castleman L, Mann C. 2002. Maltzer DS, et al. 1999.
Efficacy of Ancillary Anesthesia
• Importance of psychological preparation and support
• Music as analgesia for abortion patients receiving paracervical block ▪ 85% who wore headphones rated pain as “0,”
compared with 52% of controls• Verbicaine (“Vocal Local”)/Distraction
Therapy
Shapiro AG, Cohen H. Contraception. 1975. Stubblefield PG.Suppl Int J Gynecol Obstet. 1989.
Sharp Curettage and Pain
• Often requires increased dilatation
• Often painful• More difficult to
reduce anesthesia
Forna F, Gulmezoglu AM. Cochrane Library. 2002.
Sharp Curettage and MVA• Generally not indicated • Not routinely recommended after MVA
WHO. 2003
more…
Sharp Curettage and MVA (continued)
“…Health managers and policy makers should make all possible efforts to replace sharp curettage (D&C) with vacuum aspiration.”
WHO, 2003
WHO, Safe Abortion: Technical and Policy Guidance for Health Systems. 2003.
Pain Management Tips
Affirm patient’s viewpoint
Provide medical information
Avoid glib reassurances
Tell patient her fears are common
Help patient differentiate pain
Pain Management Options: Summary• More to pain management than avoiding pain• No pain panacea• Women should be involved• Curette check increases pain; usually not needed• Pre-procedure preparation and psychological
support can reduce anxiety and improve overall experience
Who Can Provide MVA in the United States?
• All physicians • All mid-level providers including:
▪ Physician assistants▪ Nurse practitioners ▪ Nurse midwives
• Research your state’s individual laws, rulings, and professional scopes of practice
more…
Who Can Provide MVA in the United States? (continued)
Legal use may depend upon specific diagnosis of patient:
• Incomplete abortion• Prolonged uterine bleeding• Endometrial biopsy• Elective abortion where legal
MVA Training Organizations• Association of Reproductive Health Professionals
(ARHP)• Clinician Training Initiative (CTI)—Planned
Parenthood of New York City (PPNYC)• National Abortion Federation (NAF)• Planned Parenthood® Federation of America (PPFA)• Ipas• Physicians for Reproductive Choice and Health
(PRCH)
Facilities Needed for MVA
• Privacy for counseling • Procedure room
▪ Exam table▪ Space for supplies,
processing instruments, and examining products of conception
Medications and Supplies Needed for MVA
• Analgesia• Anesthetic• Silver nitrate or ferric subsulfate• Uterotonic agent• Rhogam
more…
Medications and Supplies Needed for MVA (continued)
• Urine pregnancy tests• Emergency cart• Pharmacologic agents for cervical ripening
(optional)
Equipment Needed for MVA
Procedure• Aspirators• Cannulae• Speculae• Sharp-toothed and/or atraumatic tenaculae
more…
Equipment Needed for MVA (continued)
Procedure• Antiseptic solution• Mechanical dilators• 20-cc syringe for local anesthesia
more…
Equipment Needed for MVA (continued)
Equipment for POC Exam after MVA
Tissue examination• Basin for POC• Fine-mesh kitchen strainer• Back light or enhanced light• Tools to grasp tissue and POC• Specimen containers
Hyman AG, Castleman L. Ipas. 2005
Ultrasound and MVA
• Not required for MVA
• Used by some providers routinely
• Use contingent on provider preference and experience
Word Health Organization. 2003.
Women’s Access to Care
Leonard A, Winkler J. Adv Abortion Care. 1991.
Incorporating MVA Into Practice
What does it take to incorporate the MVA
procedure into a clinical practice?
MVA Staffing and Facilities Requirements: Summary• All physicians and advanced practice clinicians in
many states can provide MVA• Facilities requirements include medication,
supplies, equipment, and instruments• Use of ultrasound is not required
MVA Patient Intake and Counseling
Contraindications to MVA • First-trimester induced abortion—NONE• First-trimester spontaneous abortion—NONE• Completion of incomplete abortion—NONE• Suspected pregnancy—endometrial biopsy should
NOT be performed
Ipas. 2007.
Use Caution in Women with…• Uterine anomalies• Coagulation problems• Active pelvic infection • Extreme anxiety• Any condition causing the patient to be medically
unstable
Ipas. 2007.
Patient Intake Steps for MVA• Medical history• Lab work, including -hCG• Determine gestational age• Educate about procedure and
pain management• Informed consent • Discuss contraception
MacIsaac L, Darney P. Am J Obstet Gynecol. 2000. World Health Organization. 2003.
Counseling for MVA
Effective counseling occurs before, during, and after the procedure• Woman-centered • Structured completely
around the women’s needs and concerns
more…Breitbart V, Repass DC. J Am Med Womens Assoc. 2000.; Hogue CJ, et al. Epidemiol Rev. 1982; Steward FH, et al. 2004. Hyman AG, Castleman L. 2005
Counseling for MVA (continued)
• Prepare women for procedure-related effects
• Address women’s concerns about future desired pregnancies
more…Breitbart V, Repass DC. J Am Med Womens Assoc. 2000.; Hogue CJ, et al. Epidemiol Rev. 1982; Steward FH, et al. 2004. Hyman AG, Castleman L. 2005
Counseling for MVA (continued)
Picker Institute. 1999.
Quality of counseling
Patient satisfaction with care
Post-Procedure Care
• Observe for complications▪ Bleeding ▪ Pain
• Monitor pain and treat accordingly• Monitor vital signs• Check bleeding and pain
more…
Post-Procedure Care (continued)
• Give instructions for aftercare/follow-up• Discuss contraception, if appropriate• Discharge patient
▪ Tolerates oral intake (general anesthesia only)▪ Vital signs are normal▪ Bleeding is minimal
Lichtenberg ES, Shott S. Obstet Gynecol. 2003.
Instructions for Aftercare• Warning signs to call a clinician• Pain management options• Prophylactic antibiotics
▪ Many regimens effective• When to return to normal
activities
Lichtenberg ES, Shott S. Obstet Gynecol. 2003.
When Women Should Contact Clinician• Heavy bleeding with dizziness, lightheadedness• Worsening pain not relieved with medication• Flu-like symptoms lasting >24 hours• Fever or chills• Syncope• Any questions
Contraception After MVAOvulation may occur within 7–10 days post-MVA• Dispense EC with instructions for use• Can start hormonal contraceptives immediately• Can insert IUD immediately post-procedure
more…
Contraception After MVA (continued)
• Tubal ligation can be performed post-procedure or scheduled; develop interim contraception plan
• Use barrier contraceptive with first and subsequent intercourse
Module 3:Medication Abortion
Medication Abortion
Jones RK, Henshaw SK. Perspet Sex Reprod Health. 2002.
Medication Abortion Regimens
• FDA-approved regimen▪ Mifepristone 600 mg PO followed by misoprostol
400 µg orally 48 hours later• Evidence-based regimens
▪ Mifepristone 200 mg followed by 600 µg of oral misoprostol
▪ Mifepristone 200 mg followed by 800 µg of vaginal misoprostol
WHO Task Force. BJOG. 2000; Peyron R, et al. N Engl J Med. 1993.; Spitz IM, et al. N Eng J Med. 1998.; Aubény E, et al. Int J Fertil Menopausal Stud. 1995; Kahn JG, et al. Contraception. 2000.
Protocols – Medication AbortionFDA Approved Regimen(Based on evidence up to 1996)
Alternative Evidence-Based Regimen(Based on current evidence)
Gestational age:Up to 49 days after first day of last period
Gestational age:Up to 56 days after first day of last period
Gestational age:Up to 63 days after first day of last period
Mifepristone 600 mg. (swallowed in the office)
Mifepristone 200 mg.(swallowed in the office)
Mifepristone 200 mg.(swallowed in the office)
Misoprostol 400 mcg. Oral useSwallowed in the office48 hours after taking mifepristone
Misoprostol 800 mcg. Buccal useUsed at home 24-48 hours after taking mifepristonePut in the cheek to melt
Misoprostol 800 mcg. Vaginal useUsed at home 6–72 hours after taking mifepristonePut in the vagina
Office follow-up 10–15 days after taking mifepristone
Office follow-up 4–14 days after taking mifepristone
Office follow-up 4–14 days after taking mifepristone
3 office visits 2 office visits 2 office visits
RHEDI. Montifiore Medical Center. www.rhedi.org
Evidence-Based Regimens• 200-mg dose of mifepristone• Buccal or vaginal administration of misoprostol• Home use of misoprostol• Flexibility in day of vaginal misoprostol use• Flexibility in initial follow-up evaluation
Kahn JG. Contraception. 2000.; Middleton T. Contraception. 2005.; El-Rafaey H. N Engl J Med. 1995.; Schaff EA. J Fam Pract. 1997.; Schaff EA. Contraception. 1999.; Schaff EA. JAMA. 2000.; Schaff EA. Contraception. 2001.; Schaff EA. Contraception. 2000.
Medication Abortion Efficacy
Gestational age (weeks)
Complete abortion rate (%)
Time to expulsion (after misoprostol)
< 49 91–97 49%–61% within 4 hours
< 56 83–95 87%–88% within 24 hours
< 63 88
600 mg oral mifepristone/400 mcg oral misoprostol
WHO Task Force. BJOG. 2000.; Peyron R, et al. N Engl J Med. 1993. Spitz IM, et al. N Engl J Med. 1998; Winikoff B, et al. Am J Obstet Gynecol. 1997.
Medication Abortion Efficacy
Gestational age (weeks)
Complete abortion rate (%)
Time to expulsion (after misoprostol)
< 49 96–97 56% within 4 hours
50–63 89–93
200 mg oral mifepristone/600 mcg oral misoprostol
McKinley C, et al. Hum Reprod. 1993.Baird DT, et al. Hum Reprod. 1995.
Plasma Concentration of Misoprostol
Wiehe E, et al. Obstet Gynecol. 2002.; el-Refaey H, et al. N Engl J Med. 1995.Schaff EA, et al. Contraception. 2001; Zieman M, et al. Obstet Gynecol. 1997; Fjerstad, 2006.
Pla
sma
mis
opro
stol
con
cent
ratio
n (p
g/m
L)
oral (n = 10)
vaginal (n = 10)
050
100150200250300350
60 min 120 min 180 min 240 min
Medication Abortion Efficacy
Gestational age (weeks)
Complete abortion rate (%)
Time to expulsion (after misoprostol)
<56 98 93% within 4 hours
<63 95
600 mg oral mifepristone/800 mcg vaginal misoprostol
Schaff EA, et al. Contraception. 1999.el-Refaey H, et al. N Engl J Med. 1995.
Medication Abortion Efficacy
Gestational age (weeks)
Complete abortion rate (%)
Time to expulsion (after misoprostol)
< 49 98 94% within 6 hours
< 56 97–98
< 63 98
200 mg oral mifepristone/800 mcg vaginal misoprostol
Ashok PW, et al. Hum Reprod. 1998.Schaff EA, et al. Contraception. 1999.
Medication Abortion Safety Issues• Atypical presentation of infection and sepsis• Prolonged heavy vaginal bleeding
Danco Laboratories. 2005.; FDA. 2006.Green MF. N Engl J Med. 2005.
Do Not Use in Women with…• Confirmed or suspected ectopic pregnancy• IUD in place• Long-term corticosteroid use• Hemorrhagic disorders or inherited porphyrias
Danco Laboratories. 2005.
more…
Do Not Use in Women with…(continued)
• Concurrent anticoagulant use• Chronic adrenal failure• Allergy to mifepristone, misoprostol, or other
prostaglandin
Danco Laboratories. 2005.
Patient Intake Exercise
Patient Intake Steps for Medication Abortion• Medical history• Lab work• Determine gestational age• Educate about procedure and pain management• Informed consent and patient agreement• Medication guide • Discuss contraception
Danco Laboratories. 2005. World Health Organization. 2003.
Pain Management• Ibuprofen or acetaminophen initially• Oral narcotics if necessary
Grimes DA, Creinin MD. Ann Intern Med. 2004.
When Women Should Contact Clinician• Heavy bleeding with dizziness, lightheadedness• Worsening pain not relieved with medication• Flu-like symptoms lasting >24 hours• Fever or chills• Syncope• Any questions
FDA. 2006.
Clostridium sordelli Infection
• Fever may not develop• Consider other signs of infection:
▪ Weakness▪ Nausea▪ Vomiting▪ Diarrhea
FDA. 2006.
Follow-up After Medication Abortion
• Assess completion of abortion by▪ Patient history▪ Serial HCGs or sonography▪ Speculum and/or bimanual exam as indicated
• Documentation of missed follow-up• If procedure is incomplete or unsuccessful,
MVA can be used for retained POC
Contraception After Medication Abortion• Ovulation may occur within 7–10 days after abortion• Dispense EC with instructions for use• Can start hormonal contraceptives before follow-up• Can insert IUD when abortion is confirmed
Stewart FH, et al. 2004.
Becoming a Medication Abortion Provider
• Apply to distributor to obtain mifepristone: www.earlyoptionpill.com
• Training available through National Abortion Federation: www.prochoice.org
Grimes DA, Creinin MD. Ann Intern Med. 2004.
Module 4: Counseling Women on MVA Versus Medication Abortion
Factors to Consider• Duration of pregnancy• Efficacy• Safety• Side effects• Use of anesthesia• Location• Time required
Options for Terminating Pregnancy
0 12 24 Weeks LMP
Dilation and Evacuation
Electric Vacuum Aspiration
Manual Vacuum Aspiration
Methotrexate/Misoprostol
Mifepristone/Misoprostol
Amniocentesis/AmnioinfusionUterotonic/Hypertonic
Stewart FH, et al. 2004.
Efficacy of Abortion Options
Surgical and medication abortion are highly effective
0 1 2 3 4 5 6 7 8 9 10 Weeks LMP
Manual vacuum aspiration 99%
Medication abortion (oral)91%–97% 88%
98%Medication abortion
(vaginal)Edwards J, Creinin MD. Curr Probl Obstet Gynecol Fertil. 1997.Goldberg AB, et al. Obstet Guynecol. 2004; WHO Task Force. BJOG. 2000.Ashok PW, et al. Hum Reprod. 1998.
Safety of Abortion
MVA
• Uterine or cervical injury
• Infection
Surgical and medication abortion are low risk
Medication
• Infection• Heavy bleeding
Stewart FH, et al. 2004.; Danco Laboratories. 2005.FDA. 2006.; Green MF. N Engl J Med. 2005.
Expectations
MVA
• Cramping• Bleeding
Usually subside quickly
Medication
• Cramping• Bleeding• Nausea/vomiting• Diarrhea• Fever/chills• Fatigue
Grimes DA, Creinin MD. Ann Intern Med. 2004.NAF. 2006.
Location: Where Abortion Occurs
MVA
• Hospital or office setting
Medication
• Begins in hospital/office
• Occurs at home
NAF. 2006.
Time Required for Abortion
MVA
• Complete within minutes
• 1 visit to provider
Medication• Complete within
24–48 hours• 2 visits to provider
(evidence-based)
NAF. 2006.
Advantages of Abortion Options
Stewart FH, et al. 2004.NAF. 2006.
MVA• Quicker• Woman less
involved • More certain
Medication• More natural• More private• Usually avoids
surgery
Disadvantages of Abortion Options
Stewart FH, et al. 2004.NAF. 2006.
MVA• Invasive• Less private• Small risk of
injury or infection
Medication• Waiting, uncertainty• Longer bleeding,
cramping, nausea• Additional clinic visit
Appendix
Expert Medical Advisory CommitteeHerbert P. Brown, MD Clinical Associate Professor of Ob/GynUniversity of Texas Health Science CenterSan Antonio, TX
more…
Michelle Forcier, MD, MPH Adjunct Assistant Clinical Professor of Pediatrics University of North Carolina School of Pediatrics and Family Medicine and Duke University School of Pediatrics Chapel Hill, NC
Emily Godfrey, MD, MPH Assistant Professor, Department of Family Medicine University of Illinois at Chicago Chicago, IL
Expert Medical Advisory Committee (continued)
Marji Gold, MD Professor of Family and Social MedicineAlbert Einstein College of MedicineBronx, NY
Jini Tanenhaus, PA, MA Associate Vice President, Clinician Training InitiativePlanned Parenthood of New York CityNew York, NY
top related